Photophysics and ex vivo biodistribution of β-cyclodextrin-meso-tetra(m-hydroxyphenyl)porphyrin conjugate for biomedical applications

2014 ◽  
Vol 13 (8) ◽  
pp. 1185-1191 ◽  
Author(s):  
V. Kirejev ◽  
A. R. Gonçalves ◽  
C. Aggelidou ◽  
I. Manet ◽  
J. Mårtensson ◽  
...  
Keyword(s):  
Biomedical Applications ◽  
Ex Vivo ◽  
Ex Vivo Biodistribution

Photophysics andex vivobiodistribution of porphyrin (meso-tetra(m-hydroxyphenyl)porphyrin;mTHPP) and porphyrin-cyclodextrin conjugate (β-cyclodextrin-meso-tetra(m-hydroxyphenyl)porphyrin; CD-mTHPP) were investigated and compared.

scholarly journals 68Ga-radiolabeling of hepatitis E virus-like nanoparticles and evaluation of their ex vivo biodistribution in mice

2021 ◽  
Vol 96-97 ◽  
pp. S106-S107
Author(s):  
Elisavet Lambidis ◽  
Chun Chieh Chen ◽  
Mo Baikoghli ◽  
Surachet Imlimthan ◽  
Mirkka Sarparanta ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Ex Vivo ◽  
Hepatitis E ◽  
Ex Vivo Biodistribution

scholarly journals A Tumbling Magnetic Microrobot System for Biomedical Applications

Micromachines ◽  
2020 ◽  
Vol 11 (9) ◽  
pp. 861
Author(s):  
Elizabeth E. Niedert ◽  
Chenghao Bi ◽  
Georges Adam ◽  
Elly Lambert ◽  
Luis Solorio ◽  
...  
Keyword(s):  
Ultrasound Imaging ◽  
Biomedical Applications ◽  
Imaging System ◽  
Ex Vivo ◽  
Negative Control ◽  
Circular Path ◽  
Rotational Axis ◽  
Significant Difference

A microrobot system comprising an untethered tumbling magnetic microrobot, a two-degree-of-freedom rotating permanent magnet, and an ultrasound imaging system has been developed for in vitro and in vivo biomedical applications. The microrobot tumbles end-over-end in a net forward motion due to applied magnetic torque from the rotating magnet. By turning the rotational axis of the magnet, two-dimensional directional control is possible and the microrobot was steered along various trajectories, including a circular path and P-shaped path. The microrobot is capable of moving over the unstructured terrain within a murine colon in in vitro, in situ, and in vivo conditions, as well as a porcine colon in ex vivo conditions. High-frequency ultrasound imaging allows for real-time determination of the microrobot’s position while it is optically occluded by animal tissue. When coated with a fluorescein payload, the microrobot was shown to release the majority of the payload over a 1-h time period in phosphate-buffered saline. Cytotoxicity tests demonstrated that the microrobot’s constituent materials, SU-8 and polydimethylsiloxane (PDMS), did not show a statistically significant difference in toxicity to murine fibroblasts from the negative control, even when the materials were doped with magnetic neodymium microparticles. The microrobot system’s capabilities make it promising for targeted drug delivery and other in vivo biomedical applications.

scholarly journals Radiation Dosimetry of a Novel Adenosine A2A Receptor Radioligand [11C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats

2016 ◽  
Vol 19 (2) ◽  
pp. 289-297 ◽  
Author(s):  
Xiaoyun Zhou ◽  
Philip H. Elsinga ◽  
Shivashankar Khanapur ◽  
Rudi A. J. O. Dierckx ◽  
Erik F. J. de Vries ◽  
...  
Keyword(s):  
Radiation Dosimetry ◽  
Ex Vivo ◽  
Ct Imaging ◽  
Adenosine A2a Receptor ◽  
Pet Ct ◽  
A2a Receptor ◽  
Adenosine A2a ◽  
Ex Vivo Biodistribution

scholarly journals Ex vivo biodistribution of gallium-68-labeled porous silicon nanoparticles

2020 ◽  
Vol 1439 ◽  
pp. 012035
Author(s):  
V K Tishchenko ◽  
V. M. Petriev ◽  
A A Mikhailovskaya ◽  
O A Smoryzanova ◽  
A V Kabashin ◽  
...  
Keyword(s):  
Porous Silicon ◽  
Silicon Nanoparticles ◽  
Ex Vivo ◽  
Porous Silicon Nanoparticles ◽  
Gallium 68 ◽  
Ex Vivo Biodistribution

Flexible Pressure Sensors for Biomedical Applications: From Ex Vivo to In Vivo

2020 ◽  
Vol 7 (17) ◽  
pp. 2000743 ◽  
Author(s):  
Lin Li ◽  
Jiahong Zheng ◽  
Jing Chen ◽  
Zebang Luo ◽  
Yi Su ◽  
...  
Keyword(s):  
Biomedical Applications ◽  
Ex Vivo ◽  
Pressure Sensors ◽  
Flexible Pressure Sensors

The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3035-3035
Author(s):  
Sandra Heskamp ◽  
Otto C. Boerman ◽  
Janneke D.M. Molkenboer-Kuenen ◽  
Wim J.G. Oyen ◽  
Winette T.A. Van Der Graaf ◽  
...  
Keyword(s):  
Growth Factor ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Immunohistochemical Analysis ◽  
Control Group ◽  
Vascular Density ◽  
Tumor Vascularity ◽  
Bevacizumab Treatment ◽  
Ex Vivo Biodistribution

3035 Background: Bevacizumab and cetuximab are approved antibodies for treatment of patients with metastasized colorectal cancer. However, the combination of bevacizumab and cetuximab does not improve progression free survival (Tol et al. NEJM 2009). This may be explained by the disruption of tumor vascularity by bevacizumab, thereby reducing targeting of other antibodies to the tumor. The aim of this study was to determine the effect of bevacizumab on the targeting of anti-EGFR and IGF-1R antibodies in tumors with SPECT/CT imaging. Methods: Mice with subcutaneous EGFR and IGF-1R-expressing SUM149 xenografts were injected intraperitoneally with a single dose of bevacizumab (10 mg/kg). After four days, mice received an intravenous injection of 17 MBq 111In-labeled cetuximab, an anti-EGFR antibody, or R1507, an anti-IGF-1R antibody. A control group was injected with labeled hLL2 anti-CD22, an irrelevant IgG . Three days after injection, SPECT/CT images were acquired and mice were dissected for ex vivo biodistribution. Tumors were analyzed immunohistochemically to determine vascular density (CD34), EGFR and IGF-1R expression. Results: SPECT imaging revealed that bevacizumab treatment reduced targeting of anti-EGFR and anti-IGF-1R antibodies by 42% and 35%, respectively. Ex vivo biodistribution showed that uptake of 111In-cetuximab in untreated tumors was 35.2 ± 1.6 %ID/g, compared with 19.7 ± 5.3 %ID/g for bevacizumab treated tumors (p = 0.009). A similar effect was observed for 111In-R1507 (control: 26.7 ± 2.8 %ID/g, bevacizumab:18.9 ± 2.8 %ID/g, p =0.009). No significant differences in tumor uptake were observed in mice that received the irrelevant IgG. Immunohistochemical analysis showed that vascular density decreased with 40%, while EGFR and IGF-1R expression was unaltered. Conclusions: Bevacizumab treatment can significantly reduce targeting of other antibodies to tumors. This underlines the importance of timing and sequencing of bevacizumab therapy in combination with other antibodies.

Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [18F]F-PHNO

2007 ◽  
Vol 34 (2) ◽  
pp. 195-203 ◽  
Author(s):  
Neil Vasdev ◽  
Philip Seeman ◽  
Armando Garcia ◽  
Winston T. Stableford ◽  
José N. Nobrega ◽  
...  
Keyword(s):  
Ex Vivo ◽  
D3 Receptor ◽  
In Vitro Evaluation ◽  
Receptor Agonists ◽  
Dopamine D2 ◽  
Ex Vivo Biodistribution

scholarly journals Novel thermoresponsive polymer outperforming Pluronic® F127

2020 ◽  
Author(s):  
Anna Constantinou ◽  
Valeria Nele ◽  
James Doutch ◽  
Roman Moiseev ◽  
Vitaliy Khutoryanskiy ◽  
...  
Keyword(s):  
Self Assembly ◽  
Biomedical Applications ◽  
Ex Vivo ◽  
Structural Characteristics ◽  
Thermoresponsive Polymer ◽  
Scanning Calorimetry ◽  
Thermoresponsive Polymers ◽  
Crosslinked Networks ◽  
Gelation Concentration ◽  
Physically Crosslinked

Abstract Thermoresponsive polymers featuring the appropriate combination of structural characteristics, i.e. architecture, composition, and molar mass (MM), can form physically crosslinked networks in a solvent upon changes in temperature. This fascinating class of polymers finds utility in various sectors such as formulation science and tissue engineering. Here, we report a novel thermoresponsive triblock terpolymer which out-performs the most commonly used and commercially available thermoresponsive polymer, Poloxamer P407 (also known as Pluronic® F127) in terms of gelation concentration. Specifically, the in-house synthesised polymer forms gels at lower concentrations that is an advantage in biomedical applications. To elucidate the differences in their macroscale gelling behaviour, we investigate their micellization via differential scanning calorimetry, and their nanoscale self-assembly behaviour in detail by means of small-angle neutron scattering by simultaneously recording their rheological properties (Rheo-SANS). Two different gelation mechanisms for the two polymers are revealed and proposed. Ex vivo gelation study upon intracameral injections demonstrated excellent potential for its application to improve drug residence in the eye.

Dose Escalation Biodistribution, Positron Emission Tomography/Computed Tomography Imaging and Dosimetry of a Highly Specific Radionuclide-labeled Non-blocking Nanobody

2021 ◽  
Author(s):  
Yang yanling ◽  
Feng Zhao ◽  
Daquan Chen ◽  
Chao Wang ◽  
Yan Sun ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Nude Mice ◽  
Ex Vivo ◽  
Dose Range ◽  
Emission Tomography ◽  
Humanized Mice ◽  
Biodistribution Studies ◽  
Positron Emission ◽  
Pet Ct ◽  
Ex Vivo Biodistribution

Abstract Backgroud: Immunotherapy is a valuable option for the treatment of cancers, and the curative effect anti-PD-1/PD-L1 therapy correlates closely with PD-L1 expression levels. Positron emission tomography (PET) imaging of PD-L1 expression is feasible using 68Ga-NOTA-Nb109 nanobodies. 68Ga-NOTA-Nb109 was generated by radionuclide (68Ga) labeling of Nb109 using a NOTA chelator. To facilitate clinical trials, We explored the optimal dose range of 68Ga-NOTA-Nb109 in BALB/c A375-hPD-L1 tumor-burdened nude mice and C57-hPD-L1 transgenic MC38-hPD-L1 tumor-burdened mice by intravenous of a single intravenous dose of 68Ga-NOTA-Nb109 and confirmed the dose in cynomolgus monkeys. The biodistribution data of cynomolgus monkey PET images were extrapolated to estimate the radiation dose for the adult male using OLINDA2.1 software.Results: 68Ga-NOTA-Nb109 was stable in physiologic media and human serum. Ex vivo biodistribution studies showed rapid and specific uptake in A375-hPDL1 or MC38-hPDL1 tumors. The estimated ED50 was approximately 5.4 µg in humanized mice. The injected mass (0.3–100 µg in nude mice and approximately 1–100 µg in humanized mice) greatly influenced the general biodistribution, with a better tumor-to-background ratio acquired at lower doses of Nb109 (0.3–10 µg in nude mice and approximately 1 µg in humanized mice), indicating maximum uptake in tumors at administered mass doses below the estimated ED50. Therefore, a single 15 μg/kg dose was adopted for the PET/CT imaging in cynomolgus monkey. The highest specific and persistent uptake of the tracer was detected in the spleen, with the exception of the levels in the kidney and urine bladder, which was related to metabolism and excretion. The spleen-to-muscle ratio of the tracer exceeded 10 from immediately to 4 h after administration, indicating that the dose was appropriate. The estimated effective dose was calculated to yield a radiation dose of 4.1 mSv to a patient after injection of 185 MBq of 68Ga-NOTA-Nb109.Conclusion: 68Ga-NOTA-Nb109 showed specific accumulation in hPD-L1 xenografts in ex vivo biodistribution studies and monkey PET/CT imaging. The dose escalation distribution data provided a recommended dose range for further use, and the safety of the tracer was confirmed in dosimetry studies.

Sign in / Sign up

Export Citation Format

Share Document